CDK19 and head and neck squamous cell carcinoma: Given the high rate of local recurrence and controversial discussion on the use of radiotherapy and chemotherapy in patients diagnosed with HNSCC [39,42,43,44] to prevent recurrent disease, CDK19 might serve as a valuable biomarker to identify patients who benefit from aggressive therapies, once validated on independent patient cohorts.